Current Report Filing (8-k)
March 16 2021 - 4:12PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event
reported): March 15, 2021
Enzo Biochem, Inc.
(Exact Name of Registrant as Specified in
Its Charter)
New York
(State or Other Jurisdiction of Incorporation)
001-09974
|
13-2866202
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
527 Madison Avenue
|
|
New York, New York
|
10022
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
(212) 583-0100
(Registrant’s Telephone Number, Including
Area Code)
(Former Name or Former Address, if Changed
Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to
Section 12(b) of the Act:
Title of Each Class
|
|
Trading Symbol
|
|
Name of Each Exchange on Which Registered
|
Common Stock, $.01 par value
|
|
ENZ
|
|
The New York Stock Exchange
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-1 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations
and Financial Condition
On March 15, 2021, Enzo Biochem, Inc. (the
“Company”) issued a press release announcing its operating results for its second fiscal quarter ended January 31,
2021. A copy of the press release is furnished as Exhibit 99.1 attached hereto and is incorporated by reference in its entirety
into this item 2.02 of this Current Report on Form 8-K.
Item 5.02 Departure of
Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
On March 15, 2021, Enzo Biochem,
Inc. (the “Company”) issued a press release announcing that Dr. Elazar Rabbani, Founder and CEO, will step down as
CEO and transition to a scientific role with the Company once a qualified successor is identified and hired by the Board. Dr. Rabbani
will remain as a Director of the Company. A copy of the press release is furnished as Exhibit 99.1 attached hereto and is incorporated
by reference in its entirety into this item 5.02 of this Current Report on Form 8-K.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
ENZO BIOCHEM, INC.
|
|
|
|
Date: March 16, 2021
|
By:
|
/s/ David Bench
|
|
|
David Bench
|
|
|
Chief Financial Officer
|
Enzo Biochem (NYSE:ENZ)
Historical Stock Chart
From Jun 2024 to Jul 2024
Enzo Biochem (NYSE:ENZ)
Historical Stock Chart
From Jul 2023 to Jul 2024